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Abstract 
Nelfinavir (NFV) is a currently available HIV-1 protease (PR) inhibitor. Patients in 
whom NFV treatment has failed predominantly carry D30N mutants of HIV-1 PRs if 
they have been infected with the subtype B virus. In contrast, N88S mutants of HIV-1 
PRs predominantly emerge in patients in whom NFV treatment has failed and who carry 
the CRF01_AE virus. Both D30N and N88S confer resistance against NFV. However, it 
remains unclear why the non-active site mutation N88S confers resistance against NFV. 
In this study, we examined the resistance mechanism through computational simulations. 
The simulations suggested that despite the non-active site mutation, N88S causes NFV 
resistance by reducing interactions between PR and NFV. We also investigated why the 
emergence rates of D30N and N88S differ between subtype B and CRF01_AE HIV-1. 
The simulations suggested that polymorphisms of CRF01_AE PR are involved in the 
emergence rate of the drug-resistant mutants. 
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Introduction 
Human immunodeficiency virus type 1 (HIV-1) is one of the most hazardous viruses for 
humans, and there is still a risk of a worldwide HIV-1 pandemic. HIV-1 has high 
genetic variability and has been classified into three groups, labeled M, N, and O. 
Viruses in group M are further divided into subtypes, sub-subtypes, and circulating 
recombinant forms (CRFs). The subtype B virus is commonly found in HIV-1-infected 
patients in the Americas, Europe, and Japan. In contrast, developing countries suffer 
from a growing epidemic of non-subtype B viruses. 
HIV-1 proliferates with the assistance of its own aspartic protease, so-called 
HIV-1 protease (HIV-1 PR), in its life cycle. 1 HIV-1 PR is an enzyme composed of two 
identical polypeptides, each consisting of 99 amino acid residues, and its function is to 
process the viral Gag and Gag-Pol polyprotein precursors (Fig. 1A). Because this 
processing is essential for viral maturation, inhibition of PR function leads to 
incomplete viral replication and prevents the transfer to other cells. 2 Therefore, HIV-1 
PR is an attractive target for anti-HIV-1 drugs. Nine PR inhibitors (PIs)3-11 have been 
approved by the FDA and have successfully lowered the death rate due to acquired 
immune deficiency syndrome (AIDS) in advanced countries during the past decade. 
However, the currently available PIs were developed and tested only against subtype B 
PRs. Few studies have examined the susceptibility of non-subtype B viruses to those PIs, 
and no standard protocol of chemotherapy for non-subtype B viruses has been 
established. 12-17 
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Recently, Ariyoshi et al. reported that the pattern of drug-resistant mutations 
differed between subtype B and CRF01_AE (subtype AE) HIV-1. 16 Mutations of L10F, 
K20I, L33I, and N88S in PR were more frequently seen in patients infected with 
subtype AE HIV-1 than in patients infected with subtype B HIV-1. Mutations of D30N, 
A71V, and N88D in PR were found in patients with subtype B HIV-1. Most of the 
characteristic mutation patterns in that study were associated with a history of treatment 
with nelfinavir (NFV, Fig. 1B), an FDA-approved PIs. D30N and N88S are particularly 
related to resistance against NFV. 18-21 Interestingly, N88S is also known to cause 
hypersensitivity to another PI, amprenavir. We have previously suggested by 
computational simulations that D30N in subtype B PR confers resistance against NFV 
by canceling hydrogen bonds between NFV and N30. 22 In addition, we and other 
groups have proposed an explanation of why some mutations confer resistance against 
PIs by not only X-ray crystallography23-33 but also computational studies.34-41 However, 
it has not been clarified why N88S in subtype AE PR confers resistance against NFV. 
Since N88S occurs at a non-active site of PR, it is difficult to speculate on the 
mechanism of resistance. Furthermore, it has not been understood why N88S emerges 
more predominantly than D30N in patients with subtype AE HIV-1, or why D30N 
emerges more predominantly than N88S in patients with subtype B HIV-1. Subtype AE 
HIV-1 has natural polymorphisms, K20R, E35D, M36I, R41K, H69K, L89M and I93L, 
in PR unlike subtype B HIV-1 (Fig. 1C). These polymorphisms are also located at the 
non-active site of PR. It is still uncertain whether or not the polymorphisms affect the 
emergence rates of those mutations. 
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In this study, we investigated the mechanism of resistance against NFV due to 
N88S in subtype AE HIV-1 PR through computational simulations. Our simulations 
indicated that the N88S mutation creates hydrogen bonds between the D30 and S88 side 
chains. Therefore, N88S mutation reduces interactions between D30 and NFV. We also 
investigated the reason for the difference between the two subtypes in the emergence 
rate of D30N as well as that of N88S. The results indicated that, in subtype B HIV-1, 
D30N PR has a lower affinity for NFV than does N88S PR. In subtype AE HIV-1, on 
the other hand, D30N PR has a higher affinity than does N88S. Our findings suggest 
that despite the non-active site mutations, the polymorphisms regulate the emergence 
rates of these drug-resistant mutants. 
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Results 
Reconsideration of torsional force field parameters for benzamide. Before carrying 
out molecular dynamics (MD) simulations, we reconsidered torsional force field 
parameters for benzamide: CA-CA-C –N and CA-CA-C –O (Supporting Information 
Fig. S1). The benzamide group comprises a part of NFV. The benzamide moiety in 
NFV has an important interaction with D30 of PR. 22, 42 Nevertheless, the AMBER ff0343 
and general AMBER force fields44 each cause a much higher energy barrier around the 
rotatable bond between the benzene and amide groups in benzamide than that based on 
quantum chemical calculations. This is a serious problem for our simulations. The force 
field parameters for benzamide need to be carefully examined and preferably changed 
from the original AMBER force fields, as described in the AMBER Archive in 2003.45 
Since these force field parameters have not been changed in the AMBER force fields 
yet, we improved the torsional force field parameters for the benzamide moiety in NFV. 
The torsional parameters were generated in the same manner as that for the 
development of the AMBER ff03 force field.  The obtained parameters are listed in 
Table 1. We executed MD simulations using these newly developed force field 
parameters. 
Hydrogen bonds between NFV and PRs. Hydrogen bonds play an important role in 
protein-ligand bindings. First, we examined the hydrogen bonds between NFV and PR 
in each complex: wild-type (WT) PR; D30N PR; N88S PR of subtype B HIV-1 (labeled 
B(WT), B(D30N), and B(N88S), respectively); and the reference (Ref) PR, D30N PR, 
N88S PR of subtype AE HIV-1 in complex with NFV (AE(Ref), AE(D30N), and 
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AE(N88S)). We examined 1000 snapshot structures for the last 1.0 ns and identified 
direct or one-water-molecule-mediated hydrogen bonds (Table 2 and Supporting 
Information Table S1 and Fig. S2). All six PRs create similar hydrogen bond networks. 
The side chains of both D25 and D25’ interact with the central hydroxyl group of NFV 
(the atom corresponding to O3 in Fig. 1B). One water molecule mediates the interaction 
between the main chains of I50/I50’ and NFV. Furthermore, another water molecule 
mediates the interaction between D29’ and NFV. However, the interaction between 
NFV and the 30th residue has variations among the six PRs. In B(WT) and AE(Ref), 
either the main chain or the side chain of D30 makes a direct hydrogen bond with NFV. 
D30N and N88S models show different interactions between subtype B and AE PRs. 
B(D30N) has no hydrogen bond between N30 and NFV, whereas AE(D30N) has direct 
or one-water-molecule-mediated hydrogen bonds. B(N88S) frequently creates a direct 
hydrogen bond between the main chain of D30 and NFV. On the other hand, AE(N88S) 
mainly creates one-water-molecule-mediated hydrogen bonds between the main chain 
of D30 and NFV. Interestingly, the side chain of N30 in AE(D30N) is clearly closer to 
the phenol group of NFV than that of B(D30N) (Fig. 2). In contrast, the side chain of 
D30 in AE(N88S) is more distant from the phenol group of NFV than that of B(N88S). 
Hydrogen bonds of the side chain of the 30th residue with PR residues. In B(D30N) 
as well as in AE(N88S), the side chain of the 30th residue does not create any hydrogen 
bonds with NFV. To clarify the effects of the D30N and N88S mutations in detail, the 
interactions of the side chain of the 30th residue with other residues of PR were 
investigated as shown in Table 3. B(WT) and AE(Ref) have an interaction between the 
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side chains of D30 and K45. B(D30N) has direct hydrogen bonds from the side chain of 
N30 to T31 and T74. On the other hand, AE(D30N) has one-water-molecule-mediated 
hydrogen bonds from N30 to T31, T74, and N88. T31, T74, and N88 also create 
hydrogen bond networks at the non-active sites in B(WT) and AE(Ref), although D30 is 
not involved in the networks (Supporting Information Table S2). The side chains of 
D30 in both B(N88S) and AE(N88S) have either a direct hydrogen bond with the side 
chain of S88 or one-water-molecule-mediated hydrogen bonds with T31, T74, and S88. 
The mutations D30N and N88S affect those hydrogen bond networks.  
Comparison of the structures with B(WT). ?To? clarify? ?t ?h?e? effects ?o?f ? ?mutations ?a?t ? ?the? 
3?0?t ?h? and the 88th ?residues? ?o?n? the ?active? ?site? ?c?o?n?f ?o?r?m ?a?t ?ions?, ? ?t ?h?e? ?a?v?e?r ?a?g?e? ?s?t ?r ?u?c?t ?u?r ?e? ?o?f? 
?each? ?m ?o?d?e?l ? ?f ?o?r ? ?t ?h?e? ?l ?a?s?t ? 1.0 ns? ?w?a?s? ?c?o?m ?p?a?r ?e?d? ?with? ?t ?h?a?t ? ?o?f ?B(WT) ?.? Each? ?m ?o?d?e?l ? ?w?a?s ? 
?fitted ? ?t ?o? B(WT)? ?using ? ?t ?h?e? ?coordinates? ?o?f ? ??main ?chain ?a?t ?o?m?s? ?N?, ? ?C??? , ?a?n?d? ?C?,? ?a?n?d? ?t ?h?e? ?root? 
?m ?e?a?n? ?s?q?u?a?r ?e?d? ?deviation? ?( ?R?M?S ?D?) ? ?v?a?l ?u?e? ?w?a?s? ?c?a?l ?c?u?l ?a?t ?e?d? ?( ?Fig?.? ?3) ?.? When the active site 
residues of each PR are compared with those of B(WT), conformational changes are 
observed only on the active site residues around the 30th residue. AE(N88S) shows a 
large conformational change at D30 (RMSD = 1.5±0.4Å, Fig. 4). The other four 
models -- B(D30N), B(N88S), AE(Ref), and AE(D30N) --each show a slight 
conformational change at D30. When each subtype B PR is compared with the 
corresponding subtype AE PR, B(D30N) is found to have larger conformational 
changes on N30 than AE(D30N). AE(N88S) shows larger conformational changes on 
D30 than B(N88S). Next, we compared the location of NFV in each model with that of 
B(WT). The benzamide group of NFV, which interacts with the 30th residue, shows a 
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larger positional deviation than do other parts of NFV in every model (Supporting 
Information Fig. S3). 
Binding free-energy calculations. The influence of mutation or polymorphism on the 
binding free energy ? Gb  was examined for each model. Table 4 shows the results of 
MM/PBSA calculations for all of the PRs in complex with NFV. In subtype B HIV-1, 
B(D30N) reduces the binding energy with NFV from B(WT) more than B(N88S) does. 
On the other hand, in subtype AE HIV-1, AE(D30N) shows affinity with NFV, similar 
to that of AE(Ref), and has a higher affinity with NFV than AE(N88S). The results 
correspond to the emergence rates of subtypes B and AE variants in patients in whom 
NFV treatment has failed. D30N predominantly emerges in patients with subtype B 
HIV-1, whereas N88S predominantly emerges in patients with subtype AE HIV-1. We 
also investigated the contributions of the respective residues to binding free energy (Fig. 
5). In all six models, the active site residues stabilize the complex of each PR and NFV. 
When we focus on the binding energy due to the 30th residue, D30 or N30, B(D30N) 
reduces the contribution to the binding free energy in comparison with that of B(WT) 
(Fig. 6). AE(N88S) also reduces the contribution to the binding energy compared with 
that of AE(Ref). B(N88S) shows a contribution similar to that of B(WT), and 
AE(D30N) shows a contribution similar to that of AE(Ref). 
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Discussion 
In this study, we performed MD simulations of HIV-1 PRs in complex with NFV for 
the purpose of clarifying 1) the mechanism of resistance against NFV due to N88S in 
subtype AE PR and 2) the reason why the emergence rates of D30N and N88S differ 
between subtypes B and AE HIV-1.  
The 88th residue is located at a non-active site of HIV-1PR. Thus, it is 
difficult to speculate on the mechanism of resistance due to N88S. Our simulations 
indicate that N88S mutant PR has a lower affinity with NFV than does Ref PR in 
subtype AE HIV-1, owing to the following mechanism. First, a hydrogen bond between 
the side chain of D30 and the side chain of S88 is created (Fig. 7). Second, the location 
of D30 is changed. Finally, the interaction between D30 and NFV is reduced. N88S 
indirectly affects the binding between NFV and D30. Accordingly, both N88S and 
D30N are thought to confer specific resistance against NFV because the interaction with 
D30 is an essential factor for NFV binding. Indeed, it has been reported that the 
emergence of the N88S mutation is highly related to resistance against NFV. 18-21 N88D 
is another frequently observed mutation at the 88th residue of PR. It has also been 
reported that N88D changes the interactions of the 88th residue with D30, T31, and 
T74.22, 26 However, N88D hardly affects the ligand binding at the active site and does 
not cause resistance against NFV. N88S changes the interactions in a different manner 
from that of N88D. 
We then pose another question: Why does N88S emerge more frequently in 
patients with subtype AE HIV-1 in whom NFV treatment has failed than in patients 
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with subtype B HIV-1? Ariyoshi et al. reported that D30N emerged predominantly in 
patients with subtype B HIV-1, whereas N88S appeared predominantly in patients with 
subtype AE HIV-1.16 Subtype AE HIV-1 PR has some natural polymorphisms — K20R, 
E35D, M36I, R41K, H69K, L89M and I93L — unlike subtype B PR. These amino 
acids are located at non-active sites of PR. To reveal whether the polymorphisms affect 
NFV binding or what causes the difference in the emergence rates of D30N and N88S, 
we carried out simulations of NFV complexes of WT PR, D30N PR, and N88S PR of 
subtype B (B(WT), B(D30N), B(N88S)) and Ref PR, D30N PR, and N88S PR of 
subtype AE (AE(Ref), AE(D30N), AE(N88S)). AE(Ref) has an interaction with NFV 
similar to that of B(WT). On the other hand, D30N and N88S mutations show different 
effects between subtypes B and AE PRs. D30N in subtype B PR greatly reduces the 
binding affinity with NFV, because the hydrogen bonds between N30 and NFV are 
canceled as we previously reported. 22 In contrast, D30N in subtype AE PR hardly 
affects the affinity with NFV. AE(D30N) has direct or one-water-molecule-mediated 
hydrogen bonds between N30 and NFV. On the other hand, N88S in subtype AE PR 
significantly reduces the binding affinity with NFV, whereas N88S in subtype B PR 
hardly affects the affinity with NFV. In both B(N88S) and AE(N88S), a hydrogen bond 
is created between the side chain of D30 and the side chain of S88. However, the 
interactions of NFV with D30 differ between subtype B and AE PRs. B(N88S) has a 
direct hydrogen bond between the main chain of D30 and NFV, whereas AE(N88S) 
mainly has one-water-molecule-mediated hydrogen bonds between the main chain of 
D30 and NFV. D30N PR has lower affinity with NFV than does N88S PR in subtype B 
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HIV-1. In contrast, D30N PR has higher affinity than N88S PR in subtype AE HIV-1. 
These results are compatible with the results of a study by Ariyoshi et al. 16 Both D30N 
and N88S mutations in HIV-1 PRs exhibit significant losses of viral fitness. 20,21 
Therefore, D30N and N88S mutants of HIV-1 have low growth kinetics relative to WT 
or Ref variants under the condition without any PIs. Nevertheless, it is frequently 
observed that the D30N mutant emerges in patients with subtype B HIV-1 in whom 
NFV treatment has failed, and that the N88S mutant emerges in patients with subtype 
AE HIV-1. 16 These results indicate that the effectiveness of NFV is significantly 
reduced for these mutants. In contrast, N88S mutants of subtype B PR and D30N 
mutants of subtype AE PR have rarely been seen clinically. This is thought to be due 
not only to their low degree of fitness but also to their affinities with NFV comparable 
to those of subtype B WT or subtype AE Ref variants. Our simulations suggest that the 
natural polymorphisms of subtype AE PR, in spite of the non-active site mutations, 
reduce the emergence rate of D30N and increase that of N88S. 
The polymorphisms in subtype AE PR increase the emergence rate of N88S. 
However, there remains the question of which is the key mutation that affects the 
emergence rate of N88S among the polymorphisms: K20R, E35D, M36I, R41K, H69K, 
L89M, and I93L. In this study, we focused on M36I for three reasons. First, M36I is 
related to the resistance against NFV. 46 Second, N88S has been observed in 
combination with mutations at various positions, including 20, 36, 46, 63, and 77. 19 
Third, M36I is frequently observed as a polymorphism in other subtypes, namely A and 
C. 13, 14 We executed additional simulations of M36I PR, M36I/N88S PR, and 
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L10F/M36I/N88S PR of subtype B HIV-1 in complex with NFV (labeled B(M36I), 
B(M36I/N88S), and B(L10F/M36I/N88S), respectively). L10F is a mutation that is 
frequently seen in CRF01_AE HIV-1 accompanied by N88S. 16 Our simulations suggest 
that the single M36I mutation in subtype B PR does not affect NFV binding. B(M36I) 
has stable hydrogen bonds between NFV and D30 (Supporting Information Table S3 
and Fig. S4). In contrast, the combination of M36I and N88S mutations in subtype B PR 
reduces the binding affinity with NFV. B(M36I/N88S) has fewer hydrogen bonds with 
NFV than does B(M36I) or B(N88S). Furthermore, the conformational change at D30 is 
larger in B(M36I/N88S) than in B(M36I) or B(N88S) (Supporting Information Fig. S5 
and Fig. S6). B(L10F/M36I/N88S) also creates fewer hydrogen bonds between NFV 
and D30 and causes conformational alteration at D30. The polymorphism M36I reduces 
the contribution of D30 to the binding with NFV (Supporting Information Fig. S7). Our 
simulations suggest that N88S in subtype B PR reduces the binding affinity with NFV 
when it appears together with M36I. 
It is interesting that both D30N and N88S confer resistance against NFV by 
decreasing the interaction between the 30th residue and NFV. Both D30N and N88S 
affect the active site residues around the 30th residue. Other active site residues hardly 
change their interaction with NFV or their conformations. As can be seen in Fig. 2 and 
Fig. S4, the NFV-resistant PRs -- B(D30N), AE(N88S), B(M36I/N88S), and 
B(L10F/M36I/N88S) --each show an increase in distance between the 30th residue and 
NFV. The NFV-resistant N88S mutants -- AE(N88S), B(M36I/N88S) and 
B(L10F/M36I/N88S) --each have a stable direct hydrogen bond between the side chain 
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of S88 and the side chain of D30. Therefore, N88S does not appear simultaneously with 
D30N clinically. 
Prior to the MD simulations, we reconsidered torsional force field parameters 
for the benzamide moiety in NFV. This moiety has essential hydrogen bonds with D30 
of HIV-1 PR. 22, 42 Thus, those torsional parameters are expected to greatly affect the 
results of the simulations. Nevertheless, the AMBER ff0343 and general AMBER force 
fields44 each cause a much higher energy barrier around the rotatable bond between the 
benzene and amide groups in benzamide than that based on quantum chemical 
calculations (Supporting Information Fig. S1). This was a serious problem for our 
simulations. Therefore, we improved the torsional force field parameters for the 
benzamide moiety in NFV by fitting them to the energy curve obtained from quantum 
chemical calculations. Our newly developed parameters enabled us to carry out precise 
simulations of HIV-1 PR in complex with NFV. 
In this study, we not only proposed the mechanism of resistance against NFV 
of N88S in subtype AE PR but also examined the influence of the polymorphisms in 
subtype AE PR on the emergence rates of D30N and N88S mutations. N88S and the 
polymorphisms in subtype AE PR are all classified as non-active site mutations. 
Nevertheless, these mutations affect the binding of NFV. We and other groups have 
reported that the non-active site mutations affect the binding affinity of some inhibitors, 
the emergence rate of mutants, and the catalytic activity of the protease17, 22,33,36,39,41,47-50. 
For example, the polymorphisms in subtype C HIV-1 enhance the catalytic efficacy.  
However, there have been few studies on the influence of non-active site mutations 
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from structural viewpoints. There have also been few studies on the differences between 
HIV-1 subtypes. Clarification of the roles of non-active site mutations and 
polymorphisms will enable us to design potent drugs, since the currently available PIs 
were developed and tested only against subtype B PRs. Accumulation of data on the 
susceptibilities of non-subtype B viruses to the currently available PIs is also needed in 
order to establish an effective HIV-1 therapy strategy. Clarification of these 
susceptibilities will also be useful for selecting more appropriate drugs for patients. 
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Conclusions 
We proposed a mechanism of resistance against NFV due to the non-active site 
mutation N88S in CRF01_AE PR through computational simulations. CRF01_AE PR 
has polymorphisms at non-active sites, unlike subtype B PR. Nevertheless, the 
polymorphisms affect the binding affinities between NFV and PR variants that have the 
D30N or N88S mutation. The simulations suggest that N88S in CRF01_AE PR confers 
NFV resistance by reducing interaction energy between D30 and NFV. N88S creates 
hydrogen bonds between the D30 and S88 side chains, and causes conformational 
changes at D30. These changes reduce the interactions between D30 and NFV. 
Furthermore, we proposed an explanation of why the emergence rates of D30N and 
N88S differ between subtypes B and AE HIV-1. The M36I mutation seen in the natural 
polymorphisms of CRF01_AE PR is particularly involved in the difference in the 
emergence rates of D30N and N88S. 
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Experimental section 
Force field parameters. Before carrying out molecular dynamics (MD) simulations, 
we improved the torsional force field parameters for benzamide and determined the 
restrained electrostatic potential (RESP) 51 charges for NFV. The improved torsional 
parameters were generated in the same manner as that for the development of the 
AMBER ff03 force field43. First, RESP charges of benzamide were determined based on 
data from quantum chemical calculations. Geometric optimization was performed at the 
HF/6-31G(d,p) level, and the electrostatic potential was calculated at the 
B3LYP/cc-pVTZ level under the solvation condition with ether (?=4) by the IEFPCM 
method using the Gaussian03 program. 52 The partial atom charges were determined 
using the RESP method so that the atom charges could reproduce the values of the 
calculated electrostatic potential at the surrounding points of the benzamide. Charges 
were equalized between two atoms if they were the same element and had the same 
bond coordination. Second, a potential energy curve was obtained by repeating the 
energy calculations with 5-degree stepwise changes in the torsional angle around the 
torsional axis. Energy calculations were executed at the MP2/cc-pVTZ level in the ether 
phase after geometric optimizations at the HF/6-31G(d,p) level. Third, the torsional 
parameters were obtained by fitting them to the potential energies from quantum 
chemical calculations. The torsional parameter for CA-CA-C –N was assumed to be 
equal to that for CA-CA-C –O. RESP charges for NFV were also determined in the 
same manner as that described above. 
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Molecular dynamics (MD) simulations. Minimizations and MD simulations were 
carried out using the Sander module of AMBER 8. 53 The AMBER ff03 force field43 was 
used as the parameters for proteins, ions, and water molecules. The general AMBER 
force field44 and our developed force field were used as the parameters for NFV. 
We examined the structure of each of the six PRs in complex with NFV: 
wild-type (WT) PR; D30N PR; N88S PR of subtype B HIV-1 (labeled B(WT), 
B(D30N), and B(N88S), respectively); and the reference (Ref) PR, D30N PR, N88S PR 
of subtype AE HIV-1 in complex with NFV (AE(Ref), AE(D30N), and AE(N88S)). 
Additionally, we investigated the structures of M36I PR, M36I/N88S PR, and 
L10F/M36I/N88S PR of subtype B HIV-1 in complex with NFV (labeled B(M36I), 
B(M36I/N88S), and B(L10F/M36I/N88S), respectively). We used HXB2 as the WT 
sequence of subtype B HIV-1 and NH1 as the reference sequence of subtype AE 
HIV-1.54 Each initial structure for the PR in complex with NFV was modeled from the 
atom coordinates of an X-ray crystal structure (PDB code: 1OHR) 42 using the LEaP 
module. Each model was placed in a rectangular box filled with about 8000 TIP3P 
water molecules, 55 with all of the crystal water molecules remaining. The cutoff 
distance for the long-range electrostatic and the van der Waals energy terms was set to 
12.0 Å. The expansion and shrinkage of all covalent bonds connecting to hydrogen 
atoms were constrained using the SHAKE algorithm. 56 Periodic boundary conditions 
were applied to avoid the edge effect in all calculations. Energy minimization was 
achieved in three steps. First, movement was allowed only for water molecules and ions. 
Next, the ligand and the mutated residues were allowed to move in addition to the water 
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molecules and ions. Finally, all atoms were permitted to move freely. In each step, 
energy minimization was executed by the steepest descent method for the first 10000 
steps and the conjugated gradient method for the subsequent 10000 steps. After a 0.1 ns 
heating calculation until 310 K using the NVT ensemble, a 3.0 ns equilibrating 
calculation was executed at 1 atm and at 310 K using the NPT ensemble, with an 
integration time step of 2.0 fs. In the present calculations, the MD simulations showed 
no large fluctuations after about 2.0 ns equilibrating calculations (Supporting 
Information Fig. S8 and Fig. S9). Hence, atom coordinates were collected at the interval 
of 1.0 ps for the last 1.0 ns to analyze the structure in detail.  
  The protonation states of catalytic aspartates D25 and D25’ vary depending 
on the binding ligands or PRs.57 Hence, the appropriate protonation states of catalytic 
aspartates should be determined for each model. Because NFV mimics a transition state 
of catalytic reaction by HIV-1 PR, we considered two kinds of protonation states. 58-60 
One represented a combination of protonated D25 and unprotonated D25’ states, and 
the other represented the opposite combination. In order to determine the protonation 
states when NFV binds to each PR, the free energies of these two kinds of protonation 
states were compared using the calculation data obtained during 2.0-3.0 ns MD 
simulations. The free energies were calculated on the basis of the MM/PBSA method.61, 
62 We used the same parameter set for electrostatic and van der Waals energy terms as 
that was used in the MD simulations, and no cutoff was applied for the calculation. 
Since the dielectric constants for the interior of proteins are considered to be in the 
range of 2 to 4, the interior dielectric constant was set to 2.0. 63 The outer dielectric 
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constant was set to 80.0. The pbsa program was used to solve the Poisson-Boltzmann 
(PB) equation. B(D30N), B(M36I), B(L10F/M36I/N88S), and AE(D30N) were found to 
prefer the combination of protonated D25 and unprotonated D25’. The other five PRs -- 
B(WT), B(N88S), B(M36I/N88S), AE(Ref) and AE(N88S) --preferred the combination 
of unprotonated D25 and protonated D25’ (Supporting Information Table S4).  
Hydrogen bond criteria. The formation of a hydrogen bond was defined in terms of 
distance and orientation. The combination of donor D, hydrogen H, and acceptor A 
atoms with a D - H … A configuration was regarded as a hydrogen bond when the 
distance between donor D and acceptor A was shorter than 3.5 Å and the angle H-D-A 
was smaller than 60.0 degrees.  
Binding free-energy calculation. The binding free energy64 was calculated by the 
following equation: 
?Gb = ?G
int
ele +?G
int
vdw +?Gsol - T?S , 
where ?Gb  is the binding free energy in solution, ?Gintele  and ?Gintvdw  are electrostatic 
and van der Waals interaction energies between a ligand and a protein, ?Gsol  is the 
solvation energy, and ?T?S  is the contribution of conformational entropy to the 
binding. In this study, assuming that the contribution of conformational entropy to the 
change in ?Gb  is negligible among mutants, 65 we neglected the entropy term in the 
energy estimation. ?Gintele  and ?Gintvdw  were computed using the same parameter set as 
that used in the MD simulation, and no cutoff was applied to the calculation. Solvation 
energy ?Gsol  was calculated using the pbsa program. The interior dielectric constant 
was set to 2.0, and the outer dielectric constant was set to 80.0. 63 Furthermore, the 
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contribution of each residue to the binding free energy was calculated. The total binding 
free energy was decomposed into the contribution from each individual residue by the 
MM/GBSA method. The modified GB model developed by Onufriev, Bashford and 
Case66 was used to calculate the solvation energy term. To ascertain whether or not the 
MM/GBSA results were consistent with the MM/PBSA results, we compared the total 
binding free energy obtained by the MM/PBSA method with that obtained by the 
MM/GBSA method for all coordinates acquired through the MD simulation. The 
MM/GBSA results were confirmed to be highly correlated with the MM/PBSA results 
(correlation coefficient: r ? 0.998) (Supporting Information Fig. S10). 
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Table 1. Force field parameters for the torsional parameters of the benzamide part of 
NFV. 
CA-CA-C –N CA-CA-C- O 
Vn 2 n  ?  Vn 2 n  ?  
Developed parameters Developed parameters 
0.90 2 180.0 0.90 2 180.0 
0.05 4 0.0 0.05 4 0.0 
Cf.) AMBER ff03 force field Cf.) AMBER ff03 force field 
3.63 2 180.0 3.63 2 180.0 
Torsional energy is given by E =
Vn
2
[1+ cos(n? ? ?)]. 
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Table 2. Hydrogen bond networks of NFV with D30 or N30 in PR. 
Subtype B Subtype AE 
Donor Acceptor %a Donor Acceptor % 
B(WT) AE(Ref) 
N D30 O1b NFV 30.7 N D30 O1 NFV 5.7 
O1 NFV OD1/OD2 D30 31.6 O1 NFV OD1/OD2 D30 69.2 
O1 NFV O D30 42.9 O1 NFV O D30 9.0 
B(D30N) AE(D30N) 
     O1 NFV OD1 N30 25.2 
     O1 NFV O WAT766 12.6 
     O WAT766 OD1 N30 12.1 
     O1 NFV O WAT1770 8.4 
     O WAT1770 OD1 N30 6.8 
     O1 NFV O WAT8063 13.7 
     O WAT8063 OD1 N30 9.1 
B(N88S) AE(N88S) 
N D30 O1 NFV 26.7 N D30 O1 NFV 7.4 
O1 NFV OD2 D30 12.4      
O1 NFV O D30 56.7 O1 NFV O D30 27.9 
     O1 NFV O WAT6715 28.8 
     N D30 O WAT6715 28.3 
     O WAT6715 N D30 12.6 
     O WAT6715 O D30 31.8 
     O1 NFV O WAT7886 13.6 
     O WAT6715 OD1 D30 5.2 
     O WAT6715 O D30 25.5 
a Occupancy of hydrogen bonds during 2.0-3.0 ns MD simulation. 
b The atom names of NFV are shown in Fig. 1. 
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Table 3. Hydrogen bond networks of the side chain of D30 or N30 with PR residues. 
Subtype B Subtype AE 
Donor Acceptor %a Donor Acceptor % 
B(WT) AE(Ref) 
NZ K45 OD1/OD2 D30 67.0 NZ K45 OD1 D30 38.3 
B(D30N) AE(D30N) 
ND2 N30 O T74 89.7      
ND2 N30 N T31 59.5      
ND2 N30 O T31 98.1      
N T31 ND2 N30 67.9      
     ND2 N30 O WAT224 76.9 
     N T31 O WAT224 72.6 
     O WAT224 O T31 70.7 
     O WAT224 O T74 76.8 
     ND2 N88 O WAT224 39.4 
B(N88S) AE(N88S) 
OG S88 OD1 D30 34.7 OG S88 OD2 D30 77.8 
O WAT1142 OD1/OD2 D30 46.2 O WAT226 OD2 D30 33.7 
N T31 O WAT1142 38.3 OG1 T31 O WAT226 18.1 
     N T31 O WAT226 31.4 
O WAT1142 O T74 45.1 O WAT226 O T74 33.8 
OG S88 O WAT1142 40.9      
a Occupancy of hydrogen bonds during 2.0-3.0 ns MD simulation. 
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Table 4. Binding free energy of each model. 
  ?Gintele  ?Gintvdw  ?Gsol  ?Gb
 a ??Gb  b ??Gb c 
WT (B) -12.5±1.4 -71.8±3.8 15.1±1.4 -69.2±3.7 - - 
Ref (AE) -12.8±1.7 -70.8±4.0 15.1±1.5 -68.6±3.7 0.6 - 
D30N (B) -6.9±1.2 -70.5±4.1 10.9±0.9 -66.5±3.9 2.7 - 
 (AE) -7.5±1.3 -70.2±3.9 9.5±1.0 -68.2±3.7 1.0 0.4 
N88S (B) -12.0±1.3 -71.7±3.8 15.0±1.2 -68.7±3.7 0.5 - 
 (AE) -10.6±1.4 -67.8±4.0 12.8±1.9 -65.6±3.9 3.6 3.0 
Energy is presented in units of kcal/mol. 
a T?S is not included. 
b Difference from B(WT). 
c Difference from AE(Ref). 
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Figure legends 
Fig.1. A: Structure of HIV-1 PR. Locations of two catalytic aspartates, the 30th and the 
88th residues, are shown in ball and stick representation. Locations of polymorphisms 
in subtype AE PR (K20R, E35D, M36I, R41K, H69K, L89M, and I93L) are shown in 
stick representation. B: Chemical structure of NFV. C: Amino acid sequences of a 
wild-type (WT) subtype B HIV-1 PR (HXB2) and a reference sequence of subtype AE 
HIV-1 PR (NH1). The polymorphisms in subtype AE PR are highlighted in red letters. 
Fig. 2. Distance between NFV and the 30th residue. Each red and green solid line 
corresponds to the distance between N of the 30th residue and the O1 atom of NFV and 
the distance between O of the 30th residue and the O1 atom of NFV. Blue solid lines of 
B(WT), AE(Ref), B(N88S), and AE(N88S) show the distances between O1 of NFV and 
OD1/OD2 of D30, while those of B(D30N) and AE(D30N) show the distances between 
O1 of NFV and OD1/ND2 of N30. 
Fig. 3. 3D plot of RMSD of the average structure of each model from that of B(WT). 
PR in each model is shown in colored tube representation. The color refers to the 
magnitude of RMSD shown in the bottom bar. Each model was fitted to B(WT) using 
the coordinates of main chain atoms N, C? , and C of PR. The superimposed gray sticks 
and tubes represent the structure of B(WT). 
Fig. 4. The RMSD value on the 30th residue of the average structure of each PR from 
that of B(WT). Error bars show root mean squared fluctuations (RMSF). 
Fig. 5. A: Contribution of each individual residue to binding free energy. B:  
Difference in contribution of each residue to the binding energy between the respective 
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mutant and B(WT). The energies of contributions of the residues correspond to red solid 
lines, and those of B(WT) to green lines. The bottom black lines indicate the locations 
of the active site residues (R8, L23-V32, I47-I50, P81-I84, R8’, L23’-V32’, I47’-I50’, 
P81’-I84’). 
Fig. 6. Contribution of the 30th residue to binding free energy in each model. Error bars 
stand for standard deviation. 
Fig. 7. Hydrogen bond networks around the 88th residue of PR. (A) The hydrogen bond 
networks in B(WT) and (B) those in AE(N88S). 
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